Pyrvinium

Summary

Pyrvinium (CHEMBL1201303) is an approved small-molecule antineoplastic agent (ATC P02CX01); indicated across 1 condition including helminthiasis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: P02CX01
• Indications: 1 condition
• Clinical trials: 4
• Chemistry: 382.5 Da · C26H28N3+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201303
Name	Pyrvinium
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5281035
ChEBI	CHEBI:8687
ATC	P02CX01
Molecular formula	C26H28N3+
Molecular weight	382.5
InChIKey	QMHSXPLYMTVAMK-UHFFFAOYSA-N

SMILES: CC1=CC(=C(N1C2=CC=CC=C2)C)/C=C/C3=[N+](C4=C(C=C3)C=C(C=C4)N(C)C)C

IUPAC name: 2-[(E)-2-(2,5-dimethyl-1-phenylpyrrol-3-yl)ethenyl]-N,N,1-trimethylquinolin-1-ium-6-amine

ChEBI definition: A quinolinium ion that is 1-methylquinolinium substituted by dimethylamino group at position 6 and a (E)-2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl at position 2. It is a anthelminthic drug active against pinworms. The salts of pyrvinium can also be used as anticancer agents.

Pharmacological roles (ChEBI): antineoplastic agent, anthelminthic drug.

Also known as: Pyrvinium, Pyrvinium (cation), Pyrvinium cation, Pyrvinium hydroxide, Pyrvinium ion, Pyrvinum (base), pyrvinium, PYRVINIUM, Pyrvinium pamoate, PYRVINIUM PAMOATE, name

Parent form; salt/anhydrous children: CHEMBL1572280, CHEMBL1908377, CHEMBL2105340, CHEMBL4303307, CHEMBL4645638, CHEMBL5198359

Patent coverage: 643 distinct patent families (1,797 SureChEMBL compound mentions), from 5 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 46 (assay-derived). Sample: Vasopressin V2 receptor, 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, Androgen receptor, Neuronal acetylcholine receptor subunit alpha-4, Vasopressin V1a receptor, 5-hydroxytryptamine receptor 3A, Alpha-2B adrenergic receptor, Amine oxidase [flavin-containing] A, Equilibrative nucleoside transporter 1, Thromboxane A2 receptor, Progesterone receptor, Beta-1 adrenergic receptor, Muscarinic acetylcholine receptor M1, D(2) dopamine receptor, Cannabinoid receptor 1, Motilin receptor, Sodium-dependent noradrenaline transporter, 5-hydroxytryptamine receptor 2C, Adenosine receptor A1.

Bioactivity

ChEMBL activities: 29 potent at pChembl ≥ 5 of 51 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CSNK1A1	9	Kd	1	nM	CHEMBL_ACT_24662292
SLC6A2	7.7	AC50	20	nM	CHEMBL_ACT_25144876
PDCD1	7.53	IC50	29.66	nM	CHEMBL_ACT_25719110
HRH3	7.44	AC50	36	nM	CHEMBL_ACT_25200489
SLC6A3	7.34	AC50	46	nM	CHEMBL_ACT_25123826
KCNH2	6.75	AC50	180	nM	CHEMBL_ACT_25117689
AR	6.72	IC50	190	nM	CHEMBL_ACT_24824340
SYNJ1	6	IC50	1000	nM	CHEMBL_ACT_19349196
SYNJ1	6	IC50	1000	nM	CHEMBL_ACT_19355206
SYNJ2	5.9	IC50	1250	nM	CHEMBL_ACT_19349170
SYNJ2	5.9	IC50	1250	nM	CHEMBL_ACT_19355182
SYNJ2	5.9	IC50	1250	nM	CHEMBL_ACT_19456973
SLC6A4	5.75	AC50	1800	nM	CHEMBL_ACT_25150212
SHMT2	5.59	IC50	2570	nM	CHEMBL_ACT_19332955
CHRM1	5.52	AC50	3000	nM	CHEMBL_ACT_25135325
CHRM3	5.51	AC50	3100	nM	CHEMBL_ACT_25136569
GHSR	5.43	AC50	3700	nM	CHEMBL_ACT_25172632
ADORA3	5.33	AC50	4700	nM	CHEMBL_ACT_25134085
HTR2C	5.21	AC50	6200	nM	CHEMBL_ACT_25131685
AVPR2	5.19	AC50	6400	nM	CHEMBL_ACT_25163153
NPY1R	5.11	AC50	7700	nM	CHEMBL_ACT_25186409
PTGS2	5.09	AC50	8100	nM	CHEMBL_ACT_25166070
MLNR	5.08	AC50	8300	nM	CHEMBL_ACT_25189065
P15207	5.08	AC50	8300	nM	CHEMBL_ACT_25232798
HTR2B	5.06	AC50	8800	nM	CHEMBL_ACT_25227406
SLC29A1	5.01	AC50	9800	nM	CHEMBL_ACT_25141420
ADORA2A	5.01	AC50	9700	nM	CHEMBL_ACT_25152355
DRD2	5	AC50	10000	nM	CHEMBL_ACT_25140204
PGR	5	AC50	9900	nM	CHEMBL_ACT_25222946

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE2	2
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06590454	PHASE2	RECRUITING	REVerse Intestinal Metaplasia in the Stomach (REVISE)
NCT06782048	PHASE2	NOT_YET_RECRUITING	Use of Pyrvinium to Reverse Stomach Precancerous Conditions
NCT05055323	PHASE1	ACTIVE_NOT_RECRUITING	A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer
NCT03385291	Not specified	COMPLETED	Effects of Different Stimuli in Patients With Disorders of Consciousness

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).